Posted
Video length: 1 min.
A treatment for Alzheimer’s disease, which could see the light of day this year in the United States, has shown very promising results following a clinical study. A team of researchers may have found the molecule that would slow down the deterioration of cognitive faculties.
New hope for people with Alzheimer’s disease. THE Donanemab is a monoclonal antibody injected intravenously once a month. It prevents the programmed death of neurons. “These are medications that are, a priori, all the more effective when they are started very early in the disease process“, specifies Dr. Julien dumurgerneurologist at the Cognitive Neurology Center of the Hospital Lariboisiere APHP (Paris).
Difficulties
The treatment is not a miracle cure. We must watch for side effects, and plan for mass diagnostics. “These treatments can only target people in the early stages of the disease, there is a new major problem that will arise, it will be the ability to diagnose the people who will be able to have these drugs.“says Dr. Kevin RabiantDoctor of Neuroscience. Alzheimer’s disease affects one million people in France. This is the first cause of the loss of autonomy of the elderly.